CEFUDAZ -625 Tablets

CEFUDAZ -625 tablets


Each CEFUDAZ-625 tablet contains cefuroxime 500mg and potassium clavulanate 125mg.


CEFUDAZ-625 is an antibiotic combination of cefuroxime and potassium clavulanate, in which the former acts as the antibiotic with a beta-lactam ring, while the latter acts as a beta-lactamase inhibitor.

Cefuroxime: Cefuroxime is a beta-lactam antibiotic that belongs to the class of second generation cephalosporins. Like other beta-lactam antibiotics, cefuroxime interferes with the transpeptidase activity during the peptidoglycan synthesis. Cefuroxime binds to the specific Penicillin Binding proteins (PBPs) located within the cell envelope of the bacteria and prevents transpeptidation reaction, which is the last and final step of the peptidoglycan synthesis. This impaired cell wall synthesis is followed by the cellular lysis.

Potassium clavulanate: Potassium clavulanate is a semi-synthetic beta-lactamase inhibitor that is derived from Streptomyces. Just like cefuroxime, potassium clavulanate also contains a beta-lactam ring which binds to the beta-lactamase enzymes present within the bacterial cell wall. This binding protects the beta-lactam antibiotics (here cefuroxime) against beta-lactamase catalysis. In conjunction with cefuroxime, potassium clavulanate protects the antibiotic activity of the former and makes it more effective against the harmful bacteria.


  • Bacterial Infections
  • Bloodstream infections
  • Bone and Joint Infections
  • Respiratory tract infections
  • Gonorrhea and associated infections
  • Infected animal bite
  • Lyme disease
  • Urinary and genital tract infections
  • Maxillary sinusitis
  • Skin and Subcutaneous Tissue Bacterial infections
  • Streptococcal pharyngitis
  • Streptococcal tonsillitis
  • Impetigo

Dosage and Administration:

As directed by the physician


CEFUDAZ-625 tablets are contraindicated in patients with hypersensitivity towards cefuroxime and potassium clavulanate. It is also contraindicated in patients with Clostridium difficile infection, blood clotting disorders, liver problems and kidney diseases.

Adverse Effects:

Adverse effects of this medicine are accumulation of gas, cough, muscle pain, dizziness, upset stomach, diarrhea, nausea, vomiting, skin rashes and stuffy nose.


There are no sufficient and well-controlled studies when it comes to cefuroxime and potassium clavulanate administration in pregnant women and nursing mothers. Therefore, if you are pregnant or nursing, discuss with your doctor about your condition before taking this medicine.


CEFUDAZ-625 tablets are available in 10X6’s Alu Alu packing.


The medical information on this website is provided as an information resource only. The information on this website is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health provider or a medical practitioner with any questions you may have regarding a medical condition, or to assist in understanding any information or in applying information, that you might have come across, on this website. Please note that it dangerous to take any medication without doctor’s prescription or professional advice from a registered health practitioner. Make sure to follow the instructions of physician/doctor/ registered medical practitioner before using this medicine. Medical and health information changes constantly. Therefore, the information provided on this website should not be considered current, complete or exhaustive. Please consult your healthcare provider, before coming to any conclusions with respect to your health condition or for guidance about a specific medical condition. The allopathic medicine as per the law in India must be sold by retail pharmacies holding valid trading drug license only.

Keep the medicines out of the children’s reach. This product is to be stored as recommended. Do not exceed the recommended dosage. Do not use this information in place of a visit, consultation or advice of your healthcare providers.